# Prognostic differences between persistent HFrEF and HFrecEF following acute myocardial infarction

## TL;DR

This study shows that heart failure patients who recover ejection fraction after a heart attack have better outcomes than those with persistent low ejection fraction.

## Contribution

The study identifies prognostic differences and predictors of recovery between persistent HFrEF and HFrecEF following AMI.

## Key findings

- HFrecEF patients had significantly lower cardiovascular mortality compared to persistent HFrEF patients.
- Younger age and use of RAS inhibitors and beta-blockers were independent predictors of LVEF recovery.
- HFrecEF patients had a trend toward lower heart failure rehospitalization rates.

## Abstract

Acute myocardial infarction (AMI) often leads to heart failure with reduced ejection fraction (HFrEF), with some patients showing recovery of left ventricular ejection fraction (HFrecEF) over time. This study aimed to evaluate the prognostic differences between persistent HFrEF and HFrecEF.

This prospective cohort study included AMI patients with reduced LVEF (<40%) at admission. LVEF was reassessed one month later to classify patients into persistent HFrEF (LVEF <40%) or HFrecEF, defined as follow-up LVEF >40% with an absolute increase of ≥10% from baseline, in accordance with recent consensus definitions. Outcomes included cardiovascular mortality and/or rehospitalization for heart failure. Predictors of LVEF recovery were also analyzed.

Of the 679 patients analyzed, 373 (55%) had persistent HFrEF, while 306 (45%) transitioned to HFrecEF. Patients with HFrecEF were younger, had fewer comorbidities, and were more likely to receive renin-angiotensin system (RAS) inhibitors and β-blockers.Cardiovascular mortality was significantly lower in the HFrecEF group (3.3% vs. 8.3%; adjusted HR 0.37, 95% CI: 0.18–0.77, p = 0.007), as was the rate of heart failure rehospitalization (6.2% vs. 10.2%; adjusted HR 0.60, 95% CI: 0.35–1.05, p = 0.074). Independent predictors of LVEF recovery included younger age, beta-blocker use, and RAS inhibitor use.

This study emphasizes the critical role of transitioning from persistent HFrEF to HFrecEF in improving clinical outcomes for AMI patients. Tailored management approaches, combined with routine echocardiographic monitoring and adherence to optimal medical therapy, are essential for optimizing patient care and long-term prognosis.